SEC Form 4 · accession 0001203311-19-000010
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clay B Siegall
Officer — President and CEO · Director
Period of report
Mar 8, 2019
Accepted (ET)
Mar 12, 2019 · 7:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 8, 2019 | M | 12,646 | $12.16 | A | 745,259 | D | |
| Common StockF3,F1 | Mar 8, 2019 | S | 12,646 | $69.39 | D | 732,613 | D | |
| Common Stock | Mar 8, 2019 | M | 7,502 | $12.16 | A | 740,115 | D | |
| Common StockF4 | Mar 8, 2019 | S | 7,502 | $68.86 | D | 732,613 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F5 | $12.16 | Mar 8, 2019 | M | 12,646 | D | — | Aug 25, 2019 | Common Stock | 12,646 | 108,243 | D |
| Non-Qualified Stock Option (right to buy)F5 | $12.16 | Mar 8, 2019 | M | 7,502 | D | — | Aug 25, 2019 | Common Stock | 7,502 | 100,741 | D |
Explanation of responses
- F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F3Reflects sales of common stock executed in multiple transactions at prices ranging from $69.12 to $70.01. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of common stock executed in multiple transactions at prices ranging from $68.12 to $69.11. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5Shares vested at a rate of 25% on 8/25/10 and monthly thereafter until all the shares were fully vested on 8/25/13.